Biotech Values

[DewDiligence]

ACHN—My best guess is that ACHN will wait for the [phase-1 monotherapy] 3422 results due out this fall…

Yes, ordinarily I would take this as a given; however, these are not ordinary times!

Inasmuch as all serious HCV players knew that IDIX was on the block and MRK disclosed that it performed animal testing on IDIX’s nuke in combination with MRK’s PI and NS5A, it’s not inconceivable that companies who inquired about IDIX could also have signed NDAs with ACHN to conduct animal testing of ACH-3422 in various combination regimens. If this is the case, then the lack of a deal being struck for ACH-3422 (or for ACHN in its entirely) points back to the two premises mentioned in #msg-103186964.